C difficile risk
Oral Bioavailability


Requires AMS review within 72 hours. See below for more information.

100 mg IV on day 1, then 50 mg IV q12h

Child-Pugh C (score 10-15)100 mg on day 1, then 25 mg IV Q12h

No renal adjustment required

General Information

Reserved for highly resistant infections or when significant allergies restrict other options and when there is documented susceptibility.

Associated with more treatment failures than alternatives and excess mortality - Only use when alternatives are not suitable

Pseudomonas and Proteus vulgaris are inherently resistant

  • Avoid or use with caution in patients with tetracycline reactions.

  • GI side effects very prominent with significant nausea and vomiting.

  • Tetracycline related adverse events: photosensitivity, acute pancreatitis.

  • Increased liver enzymes.

  • Rash

Oral contraceptives

Documented safety concerns in bacteremia, only use if no other options

Antimicrobial class: Tetracycline derivative

Pregnancy category: D

Average serum half life: 42 hours

Biliary penetration: Therapeutic

Lung penetration: Therapeutic

CSF penetration: Insufficient data

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.